In addition to Elekta’s audited statutory Annual Report, the report also contains Elekta’s sustainability information, based on GRI Standards as well as the EU Taxonomy regulation, the Corporate Governance Report, and the Remuneration Report.
 
“Despite a challenging start, this year ended in growth,” says Gustaf Salford, Elekta’s President and CEO. “We were able to grow revenue by completing installations from our strong order backlog, and increased margins from the effects of the Cost-reduction Initiative. Looking forward, we expect the macroeconomic challenges to remain, however, we will continue to adapt and drive improvements. Next year we will focus on optimizing our recent product launches – not least Elekta ONE – driving price and margin expansion and maintaining our momentum during the second half of this fiscal year. Our purpose, to provide hope for everyone dealing with cancer, will continue to drive us forward, and together with our customers and partners, we will strive towards a world where everyone has access to the best cancer care.”
 
# # #
 
For further information, please contact:
Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com
Time zone: CEST, Central European Summer Time

About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on Twitter.